Search

Crinetics Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

84.67 0.28

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

84.4

Maximum

84.7

Fő mutatók

By Trading Economics

Bevétel

7M

-121M

Értékesítés

14M

25M

Egy részvényre jutó nyereség

-1.14

Profit margin

-481.149

Munkavállalók

594

EBITDA

-4.7M

-131M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+1.3% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

63M

8.9B

Előző nyitás

84.39

Előző zárás

84.67

Hangulat hírek alapján

By Acuity

60%

40%

292 / 340 Rangsor szerint Healthcare

Crinetics Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 13. 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

2026. aug. 13. 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

2026. aug. 13. 23:51 UTC

News

Milestone Scientific reported second-quarter sales of $2.841 million, exceeding estimates. Shares are higher in after-market hours following the earnings announcement.

2026. aug. 13. 23:51 UTC

News
Social Media

Campbell Soup Co filed for a mixed securities shelf to raise capital. Shares are higher in after-market trading amid positive social media sentiment.

2026. aug. 13. 23:51 UTC

News
Social Media

Charter Communications received final approval for its Cox acquisition, but shares are trading lower in after-market hours, reflecting downward pressure since Thursday's close.

2026. aug. 13. 23:46 UTC

News

Citi analyst Ronald Josey raised Wayfair's price target to $133.00 from $95.00, maintaining a Buy rating. Shares are trading higher in after-market hours.

2026. aug. 13. 23:46 UTC

News
Correlated Moves

Synchrony Financial shares declined in after-market hours following the appointment of Nimrod Barak as Chief AI Officer, effective June 30, 2026.

2026. aug. 13. 23:46 UTC

News

UWM Holdings Corp secures $2.05 billion investment from Oaktree and SFS Group. Shares are trading higher in after-market hours following the announcement.

2026. aug. 13. 23:41 UTC

News

EPR Properties declared a monthly cash dividend of $0.31 per share, payable September 15, 2026, as shares moved higher during after-market hours.

2026. aug. 13. 23:41 UTC

News

Credicorp Ltd reported second-quarter earnings of $7.29 per share, exceeding estimates. The stock moved higher during after-market hours following this performance.

2026. aug. 13. 23:41 UTC

Social Media
News

Eton Pharmaceuticals reported record revenue of $37.6 million and raised its full-year guidance to over $145 million, driving shares higher in after-market trading.

2026. aug. 13. 23:41 UTC

News

Norway's sovereign wealth fund increased its Bitcoin exposure through MicroStrategy investments. Bitcoin is trading lower today, remaining below its 20-day moving average.

2026. aug. 13. 23:36 UTC

News

Lucid Group Inc introduced the Lucid Gravity GT-S SUV priced at $125,900, but shares declined in after-market trading following the announcement.

2026. aug. 13. 23:31 UTC

News

Western Union shares rise in after-market trading following New York Governor Kathy Hochul's approval of its acquisition of International Money Express.

2026. aug. 13. 23:31 UTC

Correlated Moves
News
Social Media

Microsoft shares are trading lower after a report on OpenAI's $40 billion revenue run rate and Iren's $9.7 billion cloud services contract.

2026. aug. 13. 23:31 UTC

Social Media
News

Micron Technology launches a $250 million AI-focused fund, raising total commitments to $550 million. Shares are trading higher in after-market hours.

2026. aug. 13. 23:31 UTC

News
Social Media

Nu Holdings Ltd shares rose in after-market trading following strong Q2 results, with revenue of $5.9 billion surpassing estimates and net profit reaching $1.06 billion.

2026. aug. 13. 23:26 UTC

News

CoreCivic Inc shares rose in after-market trading following positive analyst ratings updates and a raised price target from Benchmark Co. to $45.00.

2026. aug. 13. 23:26 UTC

Correlated Moves
News

Diodes Inc announced a $325 million private placement of convertible senior notes due 2031. Shares are lower in after-market trading amid broader market trends.

2026. aug. 13. 23:26 UTC

News

Hewlett Packard Enterprise shares rose in after-market trading, buoyed by positive sentiment from Cisco's earnings and broader market gains.

2026. aug. 13. 23:21 UTC

News

Knight-Swift Transportation affirms quarterly cash dividend of $0.20 per share, though shares are trading lower in after-market hours.

2026. aug. 13. 23:21 UTC

News

Rapid7 Inc shares rose in after-market trading after reporting adjusted EPS of $0.44, exceeding expectations, and raising full-year guidance to $1.81.

2026. aug. 13. 23:16 UTC

News
Correlated Moves

Citigroup's U.S. Consumer Cards business will acquire Kard Financial to enhance credit card rewards for its 70 million cardmembers. Shares are little changed in after-market trading.

2026. aug. 13. 23:16 UTC

Correlated Moves
News

Sunrun Inc. shares declined in after-market trading, reflecting broader market trends. Recent financial results showed sales of $543.73 million and revenue of $869.99 million.

2026. aug. 13. 23:16 UTC

News

Jack in the Box Inc shares rose in after-market trading following UBS and Citigroup raising their price targets to $20, indicating a stable outlook.

2026. aug. 13. 23:11 UTC

News

Sabre Corp reported second-quarter revenue of $712 million and raised its full-year profitability outlook, though shares are trading lower in after-market hours.

2026. aug. 13. 23:06 UTC

Social Media
News

Tesla shares gained in after-market hours following the end of a lengthy strike by IF Metall and as Michael Burry covered his short position.

2026. aug. 13. 23:06 UTC

News

Silicon Motion Technology closed a $1.15 billion offering of Convertible Senior Notes due 2031, with shares trading higher in after-market hours.

2026. aug. 13. 23:06 UTC

News
Event

Target Corp will announce Q2 FY2026 earnings on August 19, with an estimated EPS of $2.24 and revenue of $25.7 billion. Shares showed little change after hours.

2026. aug. 13. 23:02 UTC

Social Media
News

Cboe Global Markets announced a dividend increase to $0.86 per share, effective September 15, 2026. Shares are trading higher in after-market hours.

Társak összehasonlítása

Árváltozás

Crinetics Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

1.3% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 85.56 USD  1.3%

Magas 95 USD

Alacsony 80 USD

14 Wall Street elemző 12 hónapos célárain alapulva a(z)Crinetics Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

14 ratings

2

Vétel

12

Tartás

0

Eladás

Hangulat

By Acuity

292 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat